Bispecific Antibodies | Dual-Target Research Antibodies

Explore 250+ research bispecific antibodies designed to simultaneously engage two distinct targets. Including T-cell engagers (CD3×tumor antigen), checkpoint co-targeting (PD-1×LAG-3, PD-1×TIM-3), and dual-receptor blocking formats. Produced using the same variable-region sequences as approved or clinical-stage bispecific therapeutics — supporting mechanism-of-action studies, assay development, and preclinical pharmacology. All products are designated Research Use Only (RUO) — not intended for diagnostic or therapeutic procedures. RUO

Why Researchers Choose abinScience

Dual-Target Engagement Simultaneously bind two distinct antigens — enabling T-cell redirection, immune cell co-engagement, and synergistic pathway modulation studies.

T-Cell Engager Formats CD3-based bispecific constructs targeting tumor-associated antigens (BCMA, CD19, CD20, HER2, EpCAM) — reference molecules for BiTE and bispecific therapeutic research.

Checkpoint Co-Targeting Bispecific formats combining checkpoint targets (PD-1×CTLA-4, PD-1×LAG-3, PD-L1×TIM-3) for combination immunotherapy mechanism studies.